# US 5,707,965 A · Peptides for control of intestinal motility

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,707,965 A
- Document ID: US5707965A
- Status: Granted
- Kind: A
- Application number: 07/851,440
- Filed: 1992-03-16
- Granted: 1998-01-13
- Earliest claimed: 1974-11-14
- Assignees: Intesco Laboratories, Inc.
- Inventors: Irving Goodman; Robert B. Hiatt
- Web page: https://patentgrep.com/patent/US5707965A

## CPC

- C07K 14/4703: {Inhibitors; Suppressors}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Peptides isolated from the bovine posterior pituitary gland are useful for the control of intestinal motility.

## Claims

### Claim 1

An electrophoretic homogenous Coherin A product prepared by the process comprising
(a) subjecting Coherin to continuous flow electrophoresis under conditions effective to separate therefrom a fraction having the ability to control intestinal motility and exhibiting the following characteristics:
(i) .lambda. maximum at 274 nm at pH 1;
(ii) .lambda. maximum at 240 nm and 290 nm at pH 11;
(iii) .lambda. minimum at 248 nm at pH 1;
(iv) .lambda. minimum at 233 and 272 nm at pH 11;
(v) isoelectric point at pH=6;
(vi) molecular weight ranging from 300 to 600;
(vii) soluble in water, slightly soluble in absolute ethanol and insoluble in acetone; and
(viii) containing glycine, said product being substantially free of Coherin, Coherin A.sub.1, Coherin A.sub.2, Coherin B and Coherin C;
(b) collecting said fraction; and
(c) lyophilizing the collected fraction.

### Claim 2 (depends on 1)

The product according to claim 1 wherein said electrophoresis is conducted at pH 2.0, 2.8 and 3.5.

### Claim 3 (depends on 2)

The product according to claim 2 wherein said electrophoresis is paper electrophoresis.

### Claim 4 (depends on 1)

The product according to claim 1 wherein Coherin is isolated from bovine posterior pituitary gland.

### Claim 5 (depends on 1)

The product according to claim 1 wherein said Coherin is substantially homogenous.

### Claim 6 (depends on 1)

The product according to claim 1 which is in solution.

### Claim 7 (depends on 1)

The product according to claim 1 which is in solid form.

### Claim 8 (depends on 1)

The product according to claim 1 which is substantially pure.

### Claim 9 (depends on 8)

The pharmaceutically acceptable salt of the product of claim 8.

### Claim 10 (depends on 8)

A therapeutic composition comprising a therapeutically effective amount of the product of claim 8 and a pharmaceutically acceptable carrier therefor.

### Claim 11 (depends on 8)

A method of controlling intestinal motility which comprises administering an effective amount of the product of claim 8 to a host in need of such control.

### Claim 12 (depends on 1)

The product according to claim 1 which additionally comprises further purifying the lyophilized product.

### Claim 13 (depends on 12)

The product according to claim 12 wherein purifying comprises extracting the lyophilized product with ethanol.

### Claim 14 (depends on 1)

The product according to claim 1 wherein Coherin is prepared by the process comprising:
(a) homogenizing dried bovine posterior pituitary powder in 0.2M ammonium acetate, pH 5.6, in an ice bath;
(b) centrifuging the product of (a) at 18,000.times.g at 5.degree. C. and separating therefrom the supernatant liquid;
(c) filtering the supernatant liquid of (b) through a diatomaceous filter aid;
(d) purifying the product of (c) on a DEAE cellulose column, eluted with 0.05M ammonium acetate, pH 5.6;
(e) lyophilizing the purified product and dissolving in 0.05 ammonium acetate, pH 5.6.
(f) purifying the lyophilized product of (e) in a column, using as the solid support, a cross-linked dextran gel having an exclusion limit of 10,000, with 0.05M ammonium acetate, pH 5.6, as the eluent;
(g) lyophilizing the product of (f) and purifying the lyophilized product in a column using as the solid support cross-linked dextran gel with an exclusion limit of 5,000, with 0.05M ammonium acetate, pH 5.6, as the eluent;
(h) lyophilizing the product of (g) and purifying the lyophilized product in a column using as the solid support cross linked dextran gel having an exclusion limit of 700, with 0.05M ammonium acetate as the eluent.

### Claim 15 (depends on 1)

The process according to claim 1 wherein Coherin is prepared by the process comprising:
(a) homogenizing dried bovine posterior pituitary powder in 0.2M ammonium acetate, pH 5.6, in an ice bath;
(b) centrifuging the product of (a) at 18,000.times.g at 5.degree. C. and separating therefrom the supernatant liquid;
(c) filtering the centrifuged product of (b) through a diatomaceous filter aid;
(d) purifying the filtered product of (c) on a DEAE cellulose column, eluted with 0.05M ammonium acetate, pH 5.6;
(e) lyophilizing the purified product of (d) and dissolving in 0.05M ammonium acetate, pH 5.6;
(f) purifying the lyophilized product of (e) in a column using as the solid support a cross-linked dextran gel having an exclusion limit of 10,000, with 0.05M ammonium acetate as the eluent;
(g) lyophilizing the product of step (f) and extracting the lyophilized product of step (f) with isopropanol; and
(h) dissolving the product of (g) in acetic acid and purifying the dissolved product in a column using as the solid support a cross-linked dextran gel having an exclusion limit of 700, with 0.05M ammonium acetate, pH 5.6, as the eluent.

### Claim 16 (depends on 1)

The pharmaceutically acceptable salt of the product of claim 1.

### Claim 17 (depends on 1)

A therapeutic composition comprising a therapeutically effective amount of the product of claim 1 and a pharmaceutically acceptable carrier therefor.

### Claim 18 (depends on 1)

A method of controlling intestinal motility which comprises administering an effective amount of the product of claim 1 to a host in need of such control.